Allay Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 39

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $57.5M

  • Investors
  • 19

Allay Therapeutics General Information

Description

Developer of sustained analgesic products designed to provide post-surgical pain management and recuperation for patients and physicians. The company's platform combines validated local analgesics and biopolymers in dissolvable candidates designed to deliver pain relief and address the drawbacks of opioids, enabling patients to get through the phase of recuperation in a simplified way.

Contact Information

Website
www.allaytx.com
Formerly Known As
Foundry Therapeutics 1
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2720 Zanker Road
  • San Jose, CA 95134
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2720 Zanker Road
  • San Jose, CA 95134
  • United States
+1 (650)

Allay Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allay Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D) 05-Jun-2025 $57.5M Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 21-Dec-2023 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B1) 07-Feb-2019 $26M $30.4M Completed Startup
1. Early Stage VC (Series A) 09-Jan-2017 $7M $4.4M Completed Startup
To view Allay Therapeutics’s complete valuation and funding history, request access »

Allay Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B-1 14,191,717 $0.001000 $0.09 $1.11 $1.11 1x $1.11 5.67%
Series A 4,400,000 $0.001000 $0.08 $1 $1 1x $1 1.76%
To view Allay Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Allay Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of sustained analgesic products designed to provide post-surgical pain management and recuperation for patient
Drug Discovery
San Jose, CA
39 As of 2026

Tampa, FL
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Allay Therapeutics Competitors (2)

One of Allay Therapeutics’s 2 competitors is Pacira BioSciences, a Formerly VC-backed company based in Tampa, FL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pacira BioSciences Formerly VC-backed Tampa, FL
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
You’re viewing 2 of 2 competitors. Get the full list »

Allay Therapeutics Patents

Allay Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4794785-A1 Carbocyclic and heterocyclic stat3 inhibitor compositions and methods Pending 10-Nov-2023
WO-2025102082-A1 Carbocyclic and heterocyclic stat3 inhibitor compositions and methods Inactive 10-Nov-2023
EP-4795028-A1 N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders Pending 20-Oct-2023
WO-2025085878-A1 N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders Inactive 20-Oct-2023
WO-2024145662-A1 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors Inactive 30-Dec-2022 C07D417/12
To view Allay Therapeutics’s complete patent history, request access »

Allay Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allay Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
EDBI Venture Capital Minority
HSBC Innovation Banking Corporation Minority
Maruishi Pharmaceutical Corporation Minority
Nea Venture Capital Minority
SGInnovate Corporate Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Allay Therapeutics FAQs

  • When was Allay Therapeutics founded?

    Allay Therapeutics was founded in 2017.

  • Where is Allay Therapeutics headquartered?

    Allay Therapeutics is headquartered in San Jose, CA.

  • What is the size of Allay Therapeutics?

    Allay Therapeutics has 39 total employees.

  • What industry is Allay Therapeutics in?

    Allay Therapeutics’s primary industry is Drug Discovery.

  • Is Allay Therapeutics a private or public company?

    Allay Therapeutics is a Private company.

  • What is the current valuation of Allay Therapeutics?

    The current valuation of Allay Therapeutics is .

  • What is Allay Therapeutics’s current revenue?

    The current revenue for Allay Therapeutics is .

  • How much funding has Allay Therapeutics raised over time?

    Allay Therapeutics has raised $175M.

  • Who are Allay Therapeutics’s investors?

    EDBI, HSBC Innovation Banking, Maruishi Pharmaceutical, Nea, and SGInnovate are 5 of 19 investors who have invested in Allay Therapeutics.

  • Who are Allay Therapeutics’s competitors?

    Pacira BioSciences and Vertex Pharmaceuticals are competitors of Allay Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process